Anika Therapeutics (NASDAQ: ANIK) and Strongbridge Biopharma PLC (NASDAQ:SBBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.
This table compares Anika Therapeutics and Strongbridge Biopharma PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Strongbridge Biopharma PLC||N/A||-83.83%||-34.77%|
This is a summary of current ratings and target prices for Anika Therapeutics and Strongbridge Biopharma PLC, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Strongbridge Biopharma PLC||0||0||3||0||3.00|
Strongbridge Biopharma PLC has a consensus price target of $13.33, indicating a potential upside of 89.13%. Given Strongbridge Biopharma PLC’s higher possible upside, analysts clearly believe Strongbridge Biopharma PLC is more favorable than Anika Therapeutics.
Earnings and Valuation
This table compares Anika Therapeutics and Strongbridge Biopharma PLC’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Anika Therapeutics||$111.36 million||6.81||$56.02 million||$2.26||22.89|
|Strongbridge Biopharma PLC||$1.53 million||162.82||-$39.43 million||($2.78)||-2.54|
Anika Therapeutics has higher revenue and earnings than Strongbridge Biopharma PLC. Strongbridge Biopharma PLC is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
81.3% of Anika Therapeutics shares are held by institutional investors. 6.6% of Anika Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility and Risk
Anika Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Strongbridge Biopharma PLC has a beta of 2.62, suggesting that its share price is 162% more volatile than the S&P 500.
Anika Therapeutics beats Strongbridge Biopharma PLC on 8 of the 12 factors compared between the two stocks.
About Anika Therapeutics
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
About Strongbridge Biopharma PLC
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing’s syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
What are top analysts saying about Anika Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anika Therapeutics Inc. and related companies.